Compare LYEL & CMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYEL | CMCL |
|---|---|---|
| Founded | 2018 | 1992 |
| Country | United States | Jersey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.1M | 373.1M |
| IPO Year | 2021 | 2003 |
| Metric | LYEL | CMCL |
|---|---|---|
| Price | $15.53 | $24.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $30.60 | $28.00 |
| AVG Volume (30 Days) | 160.6K | ★ 175.4K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | $38.54 |
| Revenue Next Year | $8,712.13 | N/A |
| P/E Ratio | ★ N/A | $10.88 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.56 | $15.85 |
| 52 Week High | $45.00 | $38.75 |
| Indicator | LYEL | CMCL |
|---|---|---|
| Relative Strength Index (RSI) | 59.00 | 74.09 |
| Support Level | $11.87 | $22.82 |
| Resistance Level | $15.63 | $25.36 |
| Average True Range (ATR) | 1.14 | 0.88 |
| MACD | 0.21 | 0.39 |
| Stochastic Oscillator | 60.40 | 91.61 |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Caledonia Mining Corp PLC is a gold exploration, development, and mining company. The company's segment includes Blanket, South Africa, Bilboes Oxide mine, and E&E projects. The company generates the majority of its revenue from the Blanket project. The Blanket Mine is located in the south-west of Zimbabwe and operates at a depth of approximately 750 meters below the surface. Its project includes Maligreen and Motapa.